BioSig Technologies to Present at Innovation in Medtech Dublin 2015
Gregory Cash, Chief Executive Officer to Present at Medtech Conference in Dublin, Ireland on April 15
LOS ANGELES, CA -- (Marketwired) -- 04/08/15 -- BioSig Technologies (OTCQB: BSGM), a leading medical device company, today announced that Gregory Cash, Chief Executive Officer will be presenting at the Innovation in Medtech conference in Dublin, Ireland on April 15, 2015. Medical device veteran, Gregory Cash, will join the industry-leading event to present its PURE EP™ System, a proprietary technology platform designed to improve the clinical outcomes of electrophysiology procedures.
The PURE EP System is currently in development by BioSig Technologies to provide information that can be used by electrophysiologists to help guide the ablation catheter; shorten procedure times; and reduce the complexity of maneuvers necessary for identifying ablation targets for various arrhythmias.
The Innovation in Medtech conference is a prestigious global investment and networking event for top executives in the medical device industry, which is being held in the medtech development hub of Dublin, Ireland. The conference will host upwards of 45 emerging medical technology companies.
"We are pleased with recent progress we have made with the company as well as the development of the PURE EP System and are honored to have been invited to share our status at this important conference," said Gregory Cash, Chief Executive Officer of BioSig Technologies.
BioSig Technologies' presentation will be at The Shelbourne Dublin, A Renaissance Hotel located at 27 St. Stephen's Green in Dublin, Ireland on April 15, 2015 at 8:55 a.m.
Download the agenda here: https://www.innovationinmedtech.com/wp-content/uploads/2015/04/Innovation-In-Medtech-Dublin-2015-Web-Agenda-4-6-15.pdf.
About BioSig Technologies
BioSig Technologies is a medical device company that has developed a proprietary technology platform designed to greatly improve the $3 billion electrophysiology (EP) marketplace(1) (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP System.
PURE EP System is a next-generation surface electrocardiogram and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making clinical decisions in real-time by acquiring and displaying high-fidelity cardiac signal recordings and providing guidance in identifying ablation targets -- areas of tissue to destroy that otherwise create a heart rhythm disturbance (arrhythmia).
Analysts forecast the global market for EP devices will grow at a 12.1 percent compound annual growth rate, from $2.5 billion in 2012 to $5.5 billion by 2019(1) -- making it one of the fastest growing medical device segments. Just in the US, the number of Atrial Fibrillation (AF) and Ventricular Tachycardia (VT) arrhythmia ablations is forecast to grow at 10.5 percent from 2012 to 2017(2).
BioSig intends to seek FDA 510(k) approval for the PURE EP System. The Company has already achieved proof of concept validation through UCLA EP & Animal Labs, and is collaborating with several of the nation's most prestigious cardiac arrhythmia centers including Texas Cardiac Arrhythmia Institute, UCLA Cardiac Arrhythmia Center, and Mayo Clinic.
(1) Electrophysiology Devices Market -- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013-2019
(2) HRI 2013 "Global Opportunities in Medical Devices & Diagnostics" report; triangulation of multiple sources; *AF includes left atrial tachycardia, left WPW, left atrial flutter.
Investor Relations:
Brian McLaughlin
BioSig Technologies, Inc.
bmclaughlin@biosigtech.com
917-370-9817
Media Relations:
Nathan Kappus
PR Prophets
Nathan@prprophets.com
914-837-9600
Source: BioSig Technologies Inc
Released April 8, 2015
